<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255134</url>
  </required_header>
  <id_info>
    <org_study_id>2019.0146</org_study_id>
    <nct_id>NCT04255134</nct_id>
  </id_info>
  <brief_title>Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)</brief_title>
  <acronym>BIORA-PAIN</acronym>
  <official_title>Comparison of Abatacept With Tumor Necrosis Factor Inhibitors in the Treatment of Rheumatoid Arthritis Pain: A Phase IV Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St George's, University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is increasingly recognized that although suppression of inflammation is a treatment goal&#xD;
      in rheumatoid arthritis, many people who have control of their inflammation continue to&#xD;
      experience pain. A number of studies have recently shown that by measuring further&#xD;
      characteristics of pain in rheumatoid arthritis, e.g. neuropathic pain, quantitative sensory&#xD;
      testing, compared with objective measures of inflammation, it is possible to acquire more&#xD;
      detailed information about the level of pain in relation to inflammation that a patient with&#xD;
      rheumatoid arthritis is experiencing, which could assist in developing their care.&#xD;
&#xD;
      In this study, the investigators will explore validated endpoints for pain including the&#xD;
      Visual Analogue Scale for pain, neuropathic pain scores and quantitative sensory testing for&#xD;
      pain.&#xD;
&#xD;
      The investigators will evaluate in a population-based study, the pain profile using the&#xD;
      Visual Analog Scale (VAS), neuropathic pain assessment, quantitative sensory testing (QST) by&#xD;
      pain pressure thresholds (PPT) in comparison to markers of inflammation in order to assess&#xD;
      the difference in pain outcomes between baseline pre- and post- treatment in a population of&#xD;
      participants with active Rheumatoid Arthritis treated with abatacept and Tumor Necrosis&#xD;
      Factor (TNF) inhibitors respectively. All measures will be conducted systematically in the&#xD;
      abatacept and TNF inhibitor groups pre- and post-treatment with respective biologic agents.&#xD;
      Participants with active Rheumatoid Arthritis who may be eligible for biologic treatment will&#xD;
      be screened for enrolment into the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective To examine: Pain characteristics in participants with active rheumatoid&#xD;
      arthritis receiving abatacept biologic therapy versus TNF inhibitor therapy in the form of&#xD;
      adalimumab.&#xD;
&#xD;
      To establish if there are differences in pain outcomes by patient reported scores, objective&#xD;
      measures of pain using quantitative sensory testing and inflammatory markers in participants&#xD;
      receiving biologic therapies for rheumatoid arthritis.&#xD;
&#xD;
      Population: The population being assessed in this study are participants with active&#xD;
      rheumatoid arthritis with a disease activity score of greater than 5.1.&#xD;
&#xD;
      Intervention: Subjects will be randomized to treatment with abatacept or adalimumab for&#xD;
      active rheumatoid arthritis&#xD;
&#xD;
      Comparison group: Abatacept is being compared to adalimumab therapy in the trial&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is a randomized, open label trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Visual Analogue Score for Pain</measure>
    <time_frame>0, 3, 6, 9, 12 months</time_frame>
    <description>The Visual Analogue Score for Pain is a pain score which has a numerical rating scale from 0 to 10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Neuropathic pain questionnaire: PainDETECT</measure>
    <time_frame>0, 3, 6, 9, 12 months</time_frame>
    <description>The painDETECT pain questionnaire is a numerical rated score for neuropathic pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Quantitative sensory testing</measure>
    <time_frame>0, 3, 6, 9, 12 months</time_frame>
    <description>Quantitative sensory testing measures numerical values for pain in specific regions of testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Blood markers</measure>
    <time_frame>0, 3, 6, 9, 12 months</time_frame>
    <description>Pain biomarkers in serum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug administered to participants with active rheumatoid arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator drug administered to participants with active rheumatoid arthritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept Injection</intervention_name>
    <description>Subjects will be randomized to treatment with either abatacept or adalimumab</description>
    <arm_group_label>Abatacept</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab Injection</intervention_name>
    <description>Subjects will be randomized to treatment with either abatacept or adalimumab</description>
    <arm_group_label>Adalimumab</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active rheumatoid arthritis causing pain and functional impairment with DAS28 &gt;5.1&#xD;
             -Has already received usual care for inflammatory arthritis including conventional&#xD;
             DMARD therapy e.g. methotrexate, sulfasalazine, leflunomide, hydroxychloroquine on&#xD;
             stable dose of csDMARD for at least 4 weeks prior to study drug initiation&#xD;
&#xD;
          -  Willing to participate in the study over a 12-month period&#xD;
&#xD;
          -  Desirably to have positive antibodies to cyclic citrullinated peptide (ACPA/CCP)&#xD;
&#xD;
          -  Between 18 and 75 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or pregnancy planned over next 12 months&#xD;
&#xD;
          -  Current or previous unsuccessful use of the biologics abatacept or adalimumab&#xD;
&#xD;
          -  Co-existing other autoimmune condition, e.g. systemic lupus erythematosus, -Sjogren's&#xD;
             syndrome, connective tissue disease, fibromyalgia, osteoarthritis, gout&#xD;
&#xD;
          -  Recent surgery in the last 3 months or imminent surgery in the next 12 months&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Previous history of cancer in the last 5 years&#xD;
&#xD;
          -  Previous history of multiple sclerosis&#xD;
&#xD;
          -  Uncontrolled heart failure, hypertension or diabetes mellitus&#xD;
&#xD;
          -  Known history of fibromyalgia or other chronic pain disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Sofat, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St George's, University of London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prof Sofat, MD, PhD</last_name>
    <phone>004402087251419</phone>
    <email>nsofat@sgul.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ms Koushesh, BSc, MSc</last_name>
    <phone>004402082666474</phone>
    <email>skoushes@sgul.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hotung Centre for Musculoskeletal Diseases</name>
      <address>
        <city>London</city>
        <zip>SW17 OPQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abiola Harrison</last_name>
      <email>oharriso@sgul.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Published data will be reported in publications from the trial. Data will be shared with other researchers on written request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

